SCHEMBL5127364

SCHEMBL5127364

C(#Cc1ccc(-c2nc3cnccn3c2Nc2ccccc2)o1)c1ccccn1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 13/20 0.66
ALDH1A1 P00352 8/20 0.66
KDM4E B2RXH2 6/20 0.66
HPGD P15428 4/20 0.66
HSD17B10 Q99714 3/20 0.66
ALOX15 P16050 2/20 0.66
CASP1 P29466 1/20 0.66
CASP7 P55210 1/20 0.66
MAPT P10636 9/20 0.55
PKM P14618 7/20 0.55
GFER P55789 2/20 0.50
LMNA P02545 4/20 0.49
MAPK1 P28482 4/20 0.49
BRAF P15056 2/20 0.49
HTT P42858 1/20 0.49
ATM Q13315 1/20 0.49
TDP1 Q9NUW8 1/20 0.46
PTGS2 P35354 1/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5121044 0.89 GAA (0.61) GAAALDH1A1KDM4EHPGDHSD17B10
SCHEMBL5113864 0.85 GAA (0.49) GAAALDH1A1KDM4EHPGDHSD17B10
SCHEMBL5128347 0.83 GAA (0.52) GAAALDH1A1KDM4EHPGDHSD17B10
SCHEMBL5116813 0.82 GAA (0.47) GAAALDH1A1KDM4EHPGDHSD17B10
SCHEMBL5127358 0.82 ALOX5 (0.52) GAAALDH1A1KDM4EHPGDHSD17B10
SCHEMBL5121858 0.82 GAA (0.47) GAAALDH1A1KDM4EHPGDHSD17B10
SCHEMBL5118720 0.82 PKLR (0.55) GAAALDH1A1KDM4EHPGDHSD17B10
SCHEMBL5115171 0.82 PKM (0.64) GAAALDH1A1KDM4EHPGDMAPT
SCHEMBL10016525 0.80 GAA (1.00) GAAALDH1A1KDM4EHPGDHSD17B10
SCHEMBL5127788 0.80 GAA (0.56) GAAALDH1A1KDM4EHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1791840-B1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS GRUENENTHAL GMBH (DE) 2013-11-27 EP claimed
US-7420056-B2 Substituted bicyclic imidazo-3-ylamine compounds GRUENENTHAL GMBH (DE) 2008-09-02 US claimed
US-20070155965-A1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS GRUENENTHAL GMBH. (DE) 2007-07-05 US claimed
US-7420056-B2 Substituted bicyclic imidazo-3-ylamine compounds GRUENENTHAL GMBH (DE) 2008-09-02 US disclosed
US-20070155965-A1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS GRUENENTHAL GMBH. (DE) 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155965-A1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS AADAC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PAICS GAA 234/4885ALDH1A1 2777/4885KDM4E 1336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.